ESMO, Medyouf et al

Oct 19 – 23 2018: Munich, Germany

Poster Discussion: The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS